Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort

@article{bockstiegel2026early,
  title = {{Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort}},
  author = {Tina Bockstiegel and Adam Webb and Miguel E. Aguado-Barrera and Ester Aguado-Flor and Manuel Altabas and Marianne Aznar and David Azria and Erik Briers and Renée Bultijnck and Jenny Chang-Claude and Alessandro Cicchetti and Maria Carmen De Santis and Alison Dunning and Laura Fachal and Olivia Fuentes-Rios and Alexandra Giraldo and Antonio Gómez-Caamaño and Sara Gutiérrez-Enríquez and Carsten Herskind and Philipp Heumann and Kerstie Johnson and Rudolf Kaaks and Sarah L. Kerns and Maarten Lambrecht and Eliana La Rocca and Meritxell Mollà and Tiziana Rancati and Victoria M. Reyes and Juan Camilo Rosas Romero and Barry S. Rosenstein and Dirk De Ruysscher and Petra Seibold and Rebecca M. Shearer and Hilary Stobart and R. Paul Symonds and Begoña Taboada-Valladares and Christopher J. Talbot and Ana Vega and Liv Veldeman and Marlon R. Veldwijk and Tim Ward and Catharine M.L. West and REQUITE/REQUITEplus/RADprecise consortia and Tim Rattay and Elena Sperk},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ctro.2026.101307},
  url = {https://doi.org/10.1016/j.ctro.2026.101307},
  note = {CC BY 4.0},
}

TY  - JOUR
TI  - Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort
AU  - Tina Bockstiegel
AU  - Adam Webb
AU  - Miguel E. Aguado-Barrera
AU  - Ester Aguado-Flor
AU  - Manuel Altabas
AU  - Marianne Aznar
AU  - David Azria
AU  - Erik Briers
AU  - Renée Bultijnck
AU  - Jenny Chang-Claude
AU  - Alessandro Cicchetti
AU  - Maria Carmen De Santis
AU  - Alison Dunning
AU  - Laura Fachal
AU  - Olivia Fuentes-Rios
AU  - Alexandra Giraldo
AU  - Antonio Gómez-Caamaño
AU  - Sara Gutiérrez-Enríquez
AU  - Carsten Herskind
AU  - Philipp Heumann
AU  - Kerstie Johnson
AU  - Rudolf Kaaks
AU  - Sarah L. Kerns
AU  - Maarten Lambrecht
AU  - Eliana La Rocca
AU  - Meritxell Mollà
AU  - Tiziana Rancati
AU  - Victoria M. Reyes
AU  - Juan Camilo Rosas Romero
AU  - Barry S. Rosenstein
AU  - Dirk De Ruysscher
AU  - Petra Seibold
AU  - Rebecca M. Shearer
AU  - Hilary Stobart
AU  - R. Paul Symonds
AU  - Begoña Taboada-Valladares
AU  - Christopher J. Talbot
AU  - Ana Vega
AU  - Liv Veldeman
AU  - Marlon R. Veldwijk
AU  - Tim Ward
AU  - Catharine M.L. West
AU  - REQUITE/REQUITEplus/RADprecise consortia
AU  - Tim Rattay
AU  - Elena Sperk
PY  - 2026
DA  - 2026/10/07
JO  - Clinical and Translational Radiation Oncology
DO  - 10.1016/j.ctro.2026.101307
UR  - https://doi.org/10.1016/j.ctro.2026.101307
AB  - Purpose: The international REQUITE study and its follow-up studies (RADprecise/REQUITEplus) prospectively collected longitudinal data from patients undergoing radiotherapy for breast, prostate, or lung cancer. We present data from 2057 women with breast cancer, describing patient-reported outcomes and acute and late adverse effects.  Methods: Patients were recruited between April 2014 and October 2016. Eligible patients received external-beam photon radiotherapy after breast-conserving surgery, had no metastasis at inclusion, no other malignancy within the previous five years, and no prior breast irradiation. Blood samples were collected before radiotherapy for genotyping, molecular analysis, and biobanking. Standardised assessments included CTCAE v4, EORTC QLQ-C30 and BR23, MFI, GPAQ, and DICOM/DVH data. Follow-up continued annually for two years, extending to eight years at eligible sites.  Results: Acute side effects peaked at end of radiotherapy, with erythema in 83–89% of patients. Grade ≥ 2 acute effects, including pain (11% versus 4.3%) and skin ulceration (4.8% versus 0.8%), were more frequent with normofractionation than hypofractionation. Grade ≥ 2 late effects affected between 0.6% and 16.8% of patients; skin induration was the most frequent late effect. Patient-reported outcome scores varied over time, with functional scale scores at two years similar to or higher than at baseline.  Conclusion: REQUITE provides real-world evidence of acute and late outcomes following normo- and hypofractionation, broadly consistent with published randomised trials. The dataset, combining clinical adverse effects, quality of life, dosimetric, and genetic data, is a resource for personalised radiotherapy research (www.requite.eu).
SN  - 2405-6308
ER  -